🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

John Hyngstrom

Rush University Medical Center

ORCID: 0000-0002-4833-3838

Also affiliated with The University of Texas MD Anderson Cancer Center, University of Utah, Huntsman Cancer Institute, Rush University

MedicineImmunology and MicrobiologyBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 3%percentile
0.944Author DataRank

Indexed papers

1in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

A single center case series of immune checkpoint inhibitor-induced type 1 diabetes mellitus, patterns of disease onset and long-term clinical outcome

Frontiers in Immunology(2023)10.3389/fimmu.2023.1229823
Top 21%
0.944DataRank
Top 21%26 citations

Jordan P. McPherson, Magdalena Kovacsovics-Bankowski, Joanne Jeter, Christos Vaklavas, Umang Swami +10 more

Papers

Driven by 13 papers — median percentile 79. Top paper: “Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma”.

Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma

New England Journal of Medicine(2023)10.1056/nejmoa2211437
N/A
6.5DataRank · unranked
846 citations

Megan Othus, Yuanbin Chen, G. Paul Wright, Kathleen J. Yost, John Hyngstrom +48 more

A single center case series of immune checkpoint inhibitor-induced type 1 diabetes mellitus, patterns of disease onset and long-term clinical outcome

Frontiers in Immunology(2023)10.3389/fimmu.2023.1229823
Top 21%
0.944DataRank
Top 21%26 citations

Jordan P. McPherson, Magdalena Kovacsovics-Bankowski, Joanne Jeter, Christos Vaklavas, Umang Swami +10 more

Regarding: Predicting Regional Lymph Node Recurrence in The Modern Age of Tumor-Positive Sentinel Node Melanoma

Annals of Surgical Oncology(2023)10.1245/s10434-023-13570-9
N/A
0DataRank · unranked
1 citations

John Hyngstrom, Corrado Caracò, Jonathan S. Zager, Tiina Jahkola, Tawnya L. Bowles +42 more

Response to high dose ipilimumab plus temozolomide after progression on standard or low dose ipilimumab in advanced melanoma: a retrospective analysis

Research Square(2023)10.21203/rs.3.rs-2997157/v1
N/A
0DataRank · unranked
1 citations

Muhammad Zaki Hidayatullah Fadlullah, Magdalena Kovacsovics-Bankowski, Berit Gibson, Umang Swami, Alyssa Erickson‐Wayman +14 more

Lower frequencies of circulating suppressive regulatory T cells and higher frequencies of CD4+ naïve T cells at baseline are associated with severe immune-related adverse events in immune checkpoint inhibitor-treated melanoma

Journal for ImmunoTherapy of Cancer(2024)10.1136/jitc-2023-008056
N/A
0DataRank · unranked
17 citations

Johanna M. Sweere, Connor P. Healy, Natalia Sigal, Lichun Cheng, William D. Chronister +15 more

Long-term outcomes among patients who respond within the first year to nivolumab plus ipilimumab or nivolumab monotherapy: A pooled analysis in 935 patients

European Journal of Cancer(2024)10.1016/j.ejca.2024.115119
N/A
0DataRank · unranked
14 citations

G.V. Long, John O. Larkin, Jedd D. Wolchok, J.C. Hassel, D. Schadendorf +16 more

Receptor tyrosine kinase inhibition leads to regression of acral melanoma by targeting the tumor microenvironment

Journal of Experimental & Clinical Cancer Research(2024)10.1186/s13046-024-03234-1
N/A
0DataRank · unranked
9 citations

R.L. Belote, Nelly M. Cruz, Tarek E. Moustafa, Carly Becker, Amanda Jiang +15 more

Receptor tyrosine kinase inhibition leads to regression of acral melanoma by targeting the tumor microenvironment

bioRxiv (Cold Spring Harbor Laboratory)(2024)10.1101/2024.06.15.599116
N/A
0DataRank · unranked
2 citations

R.L. Belote, Nelly M. Cruz, Tarek E. Moustafa, Carly Becker, Amanda Jiang +14 more

Association between history of viral infections and melanoma mortality

Heliyon(2024)10.1016/j.heliyon.2024.e40353
N/A
0DataRank · unranked
0 citations

Polly Creveling, Joshua J. Horns, Josh Bleicher, John Hyngstrom, Tawnya L. Bowles +4 more

Tattooing and risk of melanoma: a population-based case-control study in Utah

JNCI Journal of the National Cancer Institute(2025)10.1093/jnci/djaf235
N/A
0DataRank · unranked
8 citations

Britton Trabert, Lindsay J. Collin, Morgan M. Millar, David Kriebel, Laurie Grieshober +10 more

Ageing and endothelium‐mediated vascular dysfunction: the role of the NADPH oxidases

The Journal of Physiology(2022)10.1113/jp283208
N/A
0DataRank · unranked
13 citations

Sung Gi Noh, Soung Hun Park, Robert H.I. Andtbacka, John Hyngstrom, Russell S. Richardson +1 more

Dramatic Responses to High-Dose Ipilimumab Plus Temozolomide After Progression on Standard- or Low-Dose Ipilimumab in Advanced Melanoma

Current Oncology(2025)10.3390/curroncol32030144
N/A
0DataRank · unranked
2 citations

Muhammad Zaki Hidayatullah Fadlullah, Magdalena Kovacsovics-Bankowski, Berit Gibson, Umang Swami, Alyssa Erickson‐Wayman +14 more

Neoadjuvant PD-1 blockade in patients with resectable desmoplastic melanoma (SWOG 1512).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.9502
N/A
0DataRank · unranked
21 citations

James Moon, Zeynep Eroglu, Siwen Hu‐Lieskovan, William E. Carson, David A. Wada +15 more